Regenxbio Q1 2026 Loss: Gene Therapy Progress Amid Financial Woes

Font: Financial Modeling Prep  • May 14, 2026

Regenxbio Q1 2026 Earnings Miss: Financial Headwinds for Gene Therapy Innovator

Regenxbio Inc. (NASDAQ: RGNX) reported a wider-than-expected first-quarter 2026 loss, as revenue fell sharply from the prior year and missed analyst expectations. The company posted a GAAP net loss of $1.72 per basic and diluted share, compared with analyst expectations for a loss of $1.34 per share. Revenue totaled $6.4 million, below the consensus estimate of about $25.8 million.

Despite the financial shortfall, Regenxbio announced positive topline results from the pivotal Phase III portion of its AFFINITY DUCHENNE trial of RGX-202, its investigational gene therapy for Duchenne muscular dystrophy. The study met its primary endpoint with high statistical significance, with 93% of participants achieving more than 10% RGX-202 microdystrophin expression at Week 12. The company also reported a statistically significant correlation between microdystrophin expression and interim functional improvement.

Regenxbio is a biotechnology company focused on developing gene therapies designed to provide one-time treatments for rare and retinal diseases. Its pipeline includes RGX-202 for Duchenne muscular dystrophy, RGX-121 for MPS II, RGX-111 for MPS I, and surabgene lomparvovec, also known as ABBV-RGX-314, for wet age-related macular degeneration and diabetic retinopathy in collaboration with AbbVie.

For the quarter ended March 31, 2026, Regenxbio reported revenue of $6.4 million, down from $89.0 million in the same period a year earlier. The decrease was primarily due to the absence of a $70.0 million upfront license payment from Nippon Shinyaku that was recognized in the first quarter of 2025, as well as a $12.2 million decrease in ZOLGENSMA royalty revenue following the expiration of licensed patents in the United States in January 2026.

The company’s bottom line also weakened significantly. Regenxbio reported a net loss of $90.1 million, or $1.72 per basic and diluted share, compared with net income of $6.1 million, or $0.12 per share, in the year-ago quarter. Research and development expenses rose to $57.3 million from $53.1 million, mainly due to clinical trial expenses for RGX-202 and personnel-related costs. General and administrative expenses increased to $21.3 million from $20.3 million.

The clinical update offered a more positive counterpoint to the earnings miss. Regenxbio said RGX-202 was generally well tolerated, though two serious adverse events were reported: one case of subacute myocarditis and one case of asymptomatic liver injury. The company said both events were managed and resolved within weeks without lasting effects.

Regenxbio’s liquidity remains an important focus. The company ended the quarter with $150.5 million in cash, cash equivalents and marketable securities, down from $240.9 million at the end of 2025. Management expects this balance to fund operations into early 2027, excluding any potential milestone payments from partners. Its current ratio was approximately 2.62, based on current assets of $186.5 million and current liabilities of $71.1 million, suggesting the company has enough short-term assets to cover near-term obligations.